P95 BV, an Ampersand Capital Partners portfolio company, is proud to announce the appointment of Laurence De Moerlooze as Chief Medical Officer (CMO).

As we approach our 13th anniversary on June 16, we pause to celebrate important milestones and extend our deepest gratitude to our staff, partners and clients who have been part of our growth journey!

In a recent interview for Ampersand Capital Partners, our CEO, Thomas Verstraeten, and Chairman, Benoit Bouche shared pivotal insights into P95’s growth from an epidemiology consulting into a global comprehensive Contract Research Organization (CRO).

Almost one year from P95’s partnership with Ampersand Capital Partners, the article dives deeper into P95’s expanding global reach, client-focused capabilities, and commitment to global health that bring our company to the forefront.